Nurix's Bexobrutideg Bet Commands the Entire Valuation, But Does Thursday's Data Actually De-Risk It?

Note: These figures reflect diluted GAAP earnings per share, reported before non-recurring items, and may differ from the non-GAAP figures used by some sources.

Part 2.1: Price Behavior Around Earnings

Nurix Therapeutics typically reports earnings after market close, meaning Day 0 reflects anticipatory trading before results are released, while Day +1 captures the market's first full reaction to the actual numbers.

Historical price behavior around Nurix earnings shows significant volatility, with an average absolute Day 0 move of 5.62% and Day +1 move of 4.61%. The Day 0 trading range averages 8.50%, while Day +1 expands to 11.19%, indicating heightened volatility as the market digests results and management commentary.

The directional pattern has been mixed but leans toward initial optimism followed by next-day weakness. In the most recent July 2026 report, the stock gained 1.56% on Day 0 but sold off 6.60% the following session. This pattern of Day +1 reversals has appeared in multiple recent quarters, suggesting investors should be cautious about initial reactions and wait for the full market assessment.

The magnitude of moves has been substantial, with several quarters producing double-digit intraday ranges. The October 2024 report stands out with consecutive positive moves of 8.10% and 6.47%, while January 2026 saw a sharp 7.93% Day 0 decline. Given this history, investors should prepare for significant price swings regardless of whether the company beats or misses estimates.

Part 2.2: Options Market Expected Move

The options market is pricing a 4.68% expected move for the upcoming earnings release, which sits below the stock's average historical Day 0 move of 5.62% and Day +1 move of 4.61%. This suggests options traders are anticipating a more muted reaction than the historical average, though the 11.19% average Day +1 range indicates potential for volatility to exceed current expectations if results or guidance deviate significantly from consensus.

Part 3: What Analysts Are Saying

Analysts maintain a bullish stance on Nurix Therapeutics with an average recommendation of 4.60 out of 5.00, reflecting strong conviction in the company's long-term prospects. The consensus includes 11 Strong Buy ratings, 2 Moderate Buys, and 2 Hold ratings, with no sell recommendations among the 15 analysts covering the stock.

However, sentiment has deteriorated recently, with the average recommendation slipping from 4.63 one month ago and the Strong Buy count declining from 12 to 11. This modest cooling suggests some analysts are taking a more cautious stance heading into the print, likely reflecting concerns about near-term execution following the prior quarter's revenue miss.

The consensus price target of $33.93 implies 49.3% upside from the current price of $22.73, with individual targets ranging from a low of $25.00 to a high of $45.00. This wide range reflects differing views on the timeline and probability of clinical success, but the substantial implied upside indicates analysts believe the market is undervaluing Nurix's pipeline potential despite recent operational challenges.

Part 4: Technical Picture

The Barchart Technical Opinion currently shows a 40% Buy signal, unchanged from last week but down from 80% Buy one month ago, indicating a significant deterioration in technical momentum heading into earnings. This weakening follows a period where the stock has pulled back from its August high of $28.23.

Timeframe Analysis:

• Short-term (Hold): Neutral signal suggests near-term momentum has stalled after the recent rally
• Medium-term (50% Buy): Moderate buy signal indicates the intermediate trend remains constructive despite recent weakness
• Long-term (100% Buy): Strong buy signal reflects the powerful uptrend from the September 2025 low of $8.19

Trend Characteristics: The technical setup shows Average strength with the Weakest directional momentum, suggesting the stock is in a consolidation phase within a longer-term uptrend but lacking near-term catalysts outside of earnings.

The stock is currently trading below all short-term moving averages, sitting below the 5-day ($22.91), 10-day ($23.23), 20-day ($24.23), and 50-day ($25.23) averages. However, it remains above the 100-day ($22.57) and 200-day ($19.65) moving averages, confirming the longer-term uptrend remains intact despite recent weakness.

Key resistance levels are clustered between $23.23 and $25.23, representing the 10-day through 50-day moving averages that the stock would need to reclaim to resume its uptrend. Support sits at the 100-day moving average of $22.57, with the current price of $22.73 trading just above this critical level. The technical setup is cautionary heading into earnings—while the long-term trend remains positive, the stock's inability to hold above short-term moving averages and the recent deterioration in momentum suggest limited technical support for a strong post-earnings rally unless results significantly exceed expectations. The proximity to the 100-day moving average means a disappointing report could trigger a test of the $20 level, while a strong beat would need to reclaim the $25 area to restore bullish momentum.